Cyclovalone

Cat. No.: HY-107336

CAS No.: 579-23-7

Molecular Formula: $C_{22}H_{22}O_5$

Molecular Weight: 366.41

Target: COX

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Cyclovalone (Beveno) is a synthetic curcumin derivate, which inihibits cyclooxygenase and exhibits anti-inflammatory, antitumor and antioxidant activities[1]. Cyclovalone inhibits cell proliferation in normal and malignant prostatic cells. Cyclovalone ist orally active[2].

In Vitro

Cyclovalone (0.2-10 μg/ml) inhibits proliferations of androgen-responsive LNCaP cells and androgen-independent PC-3 cells through interfere with cell cycle transition[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line:	LNCaP and PC-3 cells
Concentration:	0.2-10 μg/ml
Incubation Time:	2-9 days
Result:	Inihibited cell proliferation in LNCaP and PC-3 cells in a time- and dose-dependent manner.

Cell Cycle Analysis[2]

Cell Line:	LNCaP and PC-3 cells
Concentration:	2 μg/ml
Incubation Time:	72 h
Result:	Decreased the numbers of LNCaP cells in G0/G1 phase, increased the numbers of cells in S-phase and G2/M phase. Decreased the numbers of PC-3 cells in G0/G1 phase, increased the numbers of cells in S-phase.

In Vivo

Cyclovalone (9.5-38 mg/kg, p.o. for 14 days) ist a prostate specific antagonist without significant toxicity in BALB/c mice[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice[2]
Dosage:	9.5-38 mg/kg/day
Administration:	p.o. for 14 days
Result:	Reduced weight of ventral prostate in a dose-dependent manner.

Animal Model:	PC-3 xenografted athymic BALB/c nude mice[2]
Dosage:	38 mg/kg
Administration:	p.o. for 20 days
Result:	Inhibited tumor growth without toxicity.

REFERENCES

[1]. Itokawa H, et al., Recent advances in the investigation of curcuminoids. Chin Med. 2008 Sep 17;3:11.

[2]. Markaverich BM, et al., Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation. Int J Oncol. 1998 May;12(5):1127-35.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA